Ein Milliarden Dollar Unternehmen wurde geboren?

 

SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.

"Protein misfolding and aggregation plays a significant role in a wide range of human diseases, including very common diseases such as Parkinson's and Alzheimer's, as well as many rare and ultra-rare diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "MANF has a unique ability to mediate protein folding in an extracellular fashion, making it potentially an ideal biologic drug candidate for a wide range of human conditions. Parkinson's continues to remain the Company's primary focus, especially in light of recently announced data where MANF demonstrated superiority over GDNF in a neurorestoration animal model of Parkinson's disease. However, the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's utility in diseases that have much smaller patient populations, and we will make a concerted effort to focus on rare and ultra-rare diseases when reviewing the results. This strategy may afford the Company an accelerated pathway to commercialization by identifying therapeutic applications for MANF that would require few small clinical trials. Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."

The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.[1]

A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

[1] http://www.fda.gov/ForIndustry/...rphanProductDesignation/default.htm

MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com  

 

 

A/S: 250M

O/S:  184.759.865

Float:113.824.251  

 

warum sollten die auf 1-3 Dollar gehen?  

Why we are going Higher!

1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.

2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.

3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.

4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.

5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."

Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.

6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!  

Das is geil: "6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!"

Es gibt noch weitere Infos:

a) Is nicht so wichtig
b) Hab ich vergessen
c) Hat der Hund gefressen
d) WEIL HALT!

hab mir mal Ihre Webseite angeschaut, und in USA Hammervolumen. Ich gönn mir mal welche.  

Musst ja nicht rein, aber wäe früh genug rein ist, der hat jetzt schon mehrere 100 % Plus in seinem Depot stehen!  

...selbst mit dem Anstieg der letzten Tage...

zum Jahresende. Da gibts im Januar ein zweites Weihnachten. Ich drück euch daumen ihr Himmelhunde!!  

ist das interessante ist nach ein wenig in der letzten Zeit wahnsinnig gestiegen.  

hier wird die Kohle gemacht. Jungs bleibt bei der Stange, es lohnt sich.  

 

der Kurs wird weiter steigen. Wahnsinnspotential.  

bin ja mal gespannt wies am Nachmittag weiter geht :-)
in den US Foren heiß empfohlen!  

http://www.finanznachrichten.de/nachrichten-2012-11/25047300…

Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.  

von 0,06 - 0,07 Dollar!  

verlinkt ist!

 

Watch for the gap up today if history repeats itself this week might see anoher 200% climb!

 

 

Between the new board member having many connections and AMBS being in direct contact with people like the co founder of Amgen we are on the verge of great things to come. Then there is the Manhattan law firm we brought on board two weeks ago the message board has been quiet about this but this is big news as well. Because we got one of the best law firms in the country to help secure a deal for the further development of our main drug line. This must have been done after the positive test results came back from the lab. Now it's a wait and see approach but when the JV is announced the gap up that morning between the closing bid and the open bid will be a historical leap! That day might be this morning or it might not be until next month but one thing is for certain the day is approaching and good things will come to thous of us who hold a long position in this stock. Good Luck to us!!

Sentiment: Strong Buy  

da werden einige sich noch ganz schön die augen reiben, wenn usa eröffnet, dieses Kurs würde ich nie und nimmer bezahlen, vielleicht später